Product name: Orlistat
Other name: (-)-Tetrahydrolipstatin;Alli;N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone;Ro 18-0647/002;Orlipastatum [INN-Latin];L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-;[(2S)-1-[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]tridecan-2-yl] 2-formamido-4-methyl-pentanoate;Tetrahydrolipstatin;Xenical;L-Leucine,N-formyl-,(1S)-1-[[(2S,3S)-3- hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester;
Wuhan port sails
Off-white solid, density: 0.976 g/cm³.
Orlistat is an obesity drug that does not act on the central nervous system. It only acts on the gastrointestinal tract, inhibits the hydrolysis of triacylglycerol to free fatty acids and monacylglycerol by inhibiting the lipase of the gastrointestinal tract, reduces the absorption of dietary fat (triacylglycerol) by intestinal mucosa, and promotes fat elimination from the body. Lipase is an enzyme necessary for the gastrointestinal tract to decompose fat. This product can combine with the serine residues of gastric and pancreatic lipase to inactivate lipase and prevent it from decomposing fat in food into free fatty acids, thus inhibiting the utilization and absorption of fat. In addition, this product can reduce the risk factors related to obesity.